Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Hannah Elizabeth Dzimitrowicz"'
Autor:
Hannah Elizabeth Dzimitrowicz, Fides Schwartz, Jordan Infield, Dylan Zhang, Ethan Ho, Yuan Wu, Rajan T. Gupta, Michael Roger Harrison
Publikováno v:
Journal of Clinical Oncology. 40:e16517-e16517
e16517 Background: Body composition (comp) is an increasingly recognized prognostic indicator in patients with cancer, but there are limited data regarding body comp measurements in patients with metastatic renal cell carcinoma (mRCC) treated with im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f914338f76e12724a942c74b309389b
https://doi.org/10.1200/jco.2022.40.16_suppl.e16517
https://doi.org/10.1200/jco.2022.40.16_suppl.e16517
Autor:
Ava Saidian, Kevin Hakimi, Justine Panian, Archana Ajmera, Pedro C. Barata, Stephanie A. Berg, Steven Lee Chang, Toni K. Choueiri, Hannah Elizabeth Dzimitrowicz, Hamid Emamekhoo, Evan Gross, Deepak Kilari, Elaine Tat Lam, Taylor Nonato, Sarah P. Psutka, Bicky Thapa, Nicole Weise, Tian Zhang, Rana R. McKay, Ithaar Derweesh
Publikováno v:
Journal of Clinical Oncology. 40:390-390
390 Background:The concept of primary systemic therapy has gained increasing traction in the management of metastatic and locally advanced Renal Cell Carcinoma (RCC). Most series have evaluated the use of tyrosine-kinase inhibitors, however, with the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ec2fba6a469b076eb5884a9c36c2c06
https://doi.org/10.1200/jco.2022.40.6_suppl.390
https://doi.org/10.1200/jco.2022.40.6_suppl.390
Autor:
Hannah Elizabeth Dzimitrowicz, Lauren E. Wilson, Bradford E. Jackson, Lisa Spees, Christopher Baggett, Melissa A. Greiner, Deborah Kaye, Tian Zhang, Daniel J. George, Charles D. Scales, Jessica Pritchard, Michael S. Leapman, Cary Philip Gross, Michaela Ann Dinan, Stephanie B. Wheeler
Publikováno v:
Journal of Clinical Oncology. 40:300-300
300 Background: Although oral anti-cancer agents (OAAs) have improved outcomes for patients with metastatic renal cell carcinoma (mRCC), most patients still die from the disease. High quality end-of-life (EOL) care remains a crucial component of opti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69cad5f1757dd030c8e3c68678ea74e3
https://doi.org/10.1200/jco.2022.40.6_suppl.300
https://doi.org/10.1200/jco.2022.40.6_suppl.300